Gut Bugs: Updates on the Treatment of Clostridium Difficile and H. pylori
-
Register
- User - $40
This lecture will review the general pathophysiology and epidemiology of C.diff and H.pylori and outline at risk populations as well as appropriate diagnostic testing and current management strategies.
Credits: 1.50 Contact Hours; 1.50 are Pharmacology
Expiration Date: December 31st, 2025
$40
LEARNING OBJECTIVES
After taking part in this educational activity, participants should be better able to:
-Discuss the epidemiology, pathogenesis and diagnosis of Clostridium Difficile (C. diff) and Helicobacter Pylori ( H. Pylori)
-Understand emerging antimicrobial resistant patterns for both diseases
-Review evidence based first line treatment strategies for C. Diff and H. Pylori
-Discuss options for management of relapse and salvage therapy when first line treatment fails
Christina Hanson, FNP-C
Nurse Practitioner
South Denver Gastroenterology
Christina received her Bachelors of Science in Nursing from Bethel University in St. Paul, MN where she graduated cum laude in 2001. In 2005, she returned to school to obtain her MSN after completing the Family Nurse Practitioner program at Regis University. She graduated with honors and was nominated for the Sigma Theta Tau Honor Society. Christina has been working at South Denver Gastroenterology since 2007 as a nurse practitioner, treating patients with both GI and liver disease and she is a sub investigator in the research department at SDGI. She is a course director and board of trustee for GHAPP and has had the opportunity to participate in educating other healthcare providers across the country as a national speaker. Christina enjoys running and traveling, and she loves spending time with her husband and two beautiful daughters playing in the mountains of Colorado.
CE INFORMATION
Obtain Your Credits
To earn credits for this activity, navigate to the Content(s) tab and complete all course components in the following order: 1) watch the course presentation video; 2) complete the course evaluation; 3) pass the post-test with a score of 2/3 (66.7%) or higher. You may retake the post-test until a passing score is achieved, at which point you will be able to view/print a copy of your certificate of completion. This online certificate will also be saved within your profile 'My Dashboard' -> 'Transcript/Certificates Earned' for future access.
Designation Statement
NPACE designates this educational activity for a maximum of 1.50 contact hours, of which 1.50 is pharmacology credit. Participants should claim only credit commensurate with the extent of their participation in the activity.
Accreditation Statement
Nurse Practitioner Associates for Continuing Education (NPACE) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).
In addition to ANCC, NPACE is approved as a provider of continuing education in nursing by: the California Board of Registered Nursing, Provider Number CEP8720 and Florida CE Broker #50-1476.
DISCLOSURES
Faculty
Contributing faculty, Christina Hanson, FNP-C has disclosed:
Salix Pharmaceutical Speaker Bureau/Advisory Board Hepatology Xifaxan
Phathom Speaker Bureau/Advisory Board GI Vonoprazan
Intercept Speaker Bureau Hepatology Ocaliva
Planners
All planners and contributors involved in this educational activity have disclosed no relevant financial relationships.
Disclaimer
The material presented in this continuing education program is being made available for educational purposes only and is not intended to represent the best or only methods, medications and/or guidelines appropriate for the medical situation discussed. Rather the material is intended to present an approach, view, statement, or opinion of the presenter(s), which may be helpful, or of interest to other practitioners and should not be used by clinicians without the evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. NPACE disclaims any liability, loss, injury, or damage incurred as a consequence, directly or indirectly, of the use and application of any information given in a presentation.
Disclosure of Unlabeled Use
This educational activity may mention the uses of products that are not approved by the FDA for the indication(s) being discussed. The presenter(s) are instructed to notify participants when they are discussing unapproved uses or investigational agents. The opinions related to unapproved uses of products are solely those of the presenter(s) and are not endorsed or recommended by NPACE. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Commercial Support
There is no commercial support for this activity.
Key:
Complete
Next
Failed
Available
Locked
